齐拉西酮与维思通治疗精神分裂症的对照研究

目的比较齐拉西酮与维思通治疗首发精神分裂症的疗效及安全性。方法将60例首发精神分裂症患者随机分为齐拉西酮组30例和维思通组30例,齐拉西酮组剂量范围20-120mg/天,维思通组剂量范围4-6mg/天,疗效8周。采用阳性与阴性症状量表(PANSS)评定临床疗效,副反应量表(TESS)评定药物不良反应。结果齐拉西酮组有效率为86.4%,维思通有效率为84.6%,两药疗效无显著性差异。齐拉西酮组不良反应较维思通组少,其中震颤、静坐不能等锥体外系症状的发生率显著少于维思通组(P<0.01),未出现严重反应。结论齐拉西酮与维思通治疗首发发精神分裂症的疗效相当,某些不良反应较维思通轻而少,尤其适用精神分裂症患者服用,是一种有效、耐受性好的抗精神病药物。

Comparative Study of Ziprasidone and Risperidone in the Treatment of Schizophrenia

Objective To compare efficacy and safety of domestic Ziprasidone and Risperidone in the treatment of schizophrenia.Methods Patients who met CCMD-3 for schizophrenia were randomized in two groups:Ziprasidone group(n=30) and Risperidone group(n=30).The range of dosage for the Ziprasidone group was 20-160mg/d, the range of dosage for the Risperidone group was 4-6mg/d,the treatment duration was 8 weeks. The PANSS,TESS and related lab tests were employed for assessing the treatment effectiveness and side effects. Results At the end of treatment,total effective rate was 86.4% in Ziprasidone group and 84.6% in Risperidone group,which was no significant difference between two groups.However,patients in Ziprasidone group were fewer side effects than those in Risperidone group,especially in the EPS.In Ziprasidone group mentruation disorder lactation,male,s mammo-development,lack of sexuality and erective dysfunction did not appear.Conclusion Domestic Ziprasidone has similar efficacy to Risperidone,but has less side effects.It is suitable to the patients who are sensitive to the EPS and PRL particularly.